title: At least seven days delayed stenting using minimalist immediate mechanical intervention (MIMI) in ST-segment elevation myocardial infarction: the SUPER-MIMI study.
abstract: OBJECTIVE
  The aim of this study was to ascertain whether a minimalist immediate mechanical intervention (MIMI) aiming to restore an optimal Thrombolysis In Myocardial Infarction (TIMI) flow in the culprit artery, followed ≥7 days later by a second percutaneous coronary intervention with intentional stenting, is safe in patients with ST-segment elevation myocardial infarction and large thrombotic burden.
  
  
  RESULTS
  SUPER-MIMI was a prospective, observational trial conducted between January 2014 and April 2015 in 14 French centres. A total of 155 patients were enrolled. The pharmacological therapy was left to the operator's discretion. Eighty-one patients (52.3%) had glycoprotein IIb/IIIa inhibitors (GPI) initiated before the end of the first procedure. The median (interquartile range [IQR]) delay between the two procedures was eight (seven to 12) days. Infarct-related artery reocclusion between the two procedures (primary endpoint) occurred in two patients (1.3%), neither of whom received GPI treatment. TIMI flow was maintained or improved between the end of the first procedure and the beginning of the second procedure in all patients. Thrombotic burden and stenosis severity diminished significantly between the two procedures. Stents were ultimately implanted in 97 patients (62.6%).
  
  
  CONCLUSIONS
  Deferred stenting (≥7 days) in patients with a high thrombus burden was safe on a background of GPI therapy.
authors.affiliation: Annecy-Genevois Hospital, Annecy, France.
authors.forename: Petru
authors.initials: P
authors.lastname: Mester
authors.forename: Helene
authors.initials: H
authors.lastname: Bouvaist
authors.forename: Nicolas
authors.initials: N
authors.lastname: Delarche
authors.forename: Frédéric
authors.initials: F
authors.lastname: Bouisset
authors.forename: Mohamed
authors.initials: M
authors.lastname: Abdellaoui
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Petiteau
authors.forename: Olivier
authors.initials: O
authors.lastname: Dubreuil
authors.forename: Ziad
authors.initials: Z
authors.lastname: Boueri
authors.forename: Mohamed
authors.initials: M
authors.lastname: Chettibi
authors.forename: Géraud
authors.initials: G
authors.lastname: Souteyrand
authors.forename: Hend
authors.initials: H
authors.lastname: Madiot
authors.forename: Loic
authors.initials: L
authors.lastname: Belle
mesh_terms: D000328:Adult; D000368:Aged; D017023:Coronary Angiography / Q000379:methods; D003326:Coronary Circulation / Q000187:drug effects; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use*; D011446:Prospective Studies; D000072657:ST Elevation Myocardial Infarction / Q000628:therapy*; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D005343:Fibrinolytic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex